Literature DB >> 28769187

GUIDELINES FOR AUTOPSY IN HIV POSITIVE CASES.

J R Bhardwaj1.   

Abstract

Autopsy on a patient who had died as a consequence of acquired immune deficiency syndrome (AIDS) can be of great value in understanding the disease process. A potential risk to the prosector for acquiring the HIV exists, but if adequate preventive measures are undertaken, the risk is negligible. Indeed there is no documented evidence of a pathologist or an autopsy room attendant acquiring HIV infection while performing autopsy on a patient with AIDS. The procedures to be followed in the autopsy of the patient with AIDS are discussed.

Entities:  

Keywords:  Acquired immune deficiency syndrome (AIDS); Autopsy; Autopsy in HIV Positive; Hospital acquired infections

Year:  2017        PMID: 28769187      PMCID: PMC5529695          DOI: 10.1016/S0377-1237(17)31018-3

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  5 in total

1.  Human T-lymphotropic virus type III/lymphadenopathy-associated virus: agent summary statement.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1986-08-29       Impact factor: 17.586

2.  HTLV-III/LAV seroconversion following a deep intramuscular needlestick injury.

Authors:  R L Stricof; D L Morse
Journal:  N Engl J Med       Date:  1986-04-24       Impact factor: 91.245

Review 3.  The autopsy in acquired immunodeficiency syndrome. How and why.

Authors:  S A Geller
Journal:  Arch Pathol Lab Med       Date:  1990-03       Impact factor: 5.534

Review 4.  Infection with human immunodeficiency virus in the hospital. Epidemiology, infection control, and biosafety considerations.

Authors:  J E Conte
Journal:  Ann Intern Med       Date:  1986-11       Impact factor: 25.391

5.  Unrecognized human immunodeficiency virus infection in emergency department patients.

Authors:  G D Kelen; S Fritz; B Qaqish; R Brookmeyer; J L Baker; R L Kline; R M Cuddy; T K Goessel; D Floccare; K A Williams
Journal:  N Engl J Med       Date:  1988-06-23       Impact factor: 91.245

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.